Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

被引：79
作者：
Gault, VA [1 ]
O'Harte, FPM [1 ]
Flatt, PR [1 ]
机构：
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
来源：
NEUROPEPTIDES | 2003年 / 37卷 / 05期
关键词：
D O I：
10.1016/j.npep.2003.09.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucose-dependent insulinotropic polypeptide (GIP or gastric inhibitory polypeptide) is a gastrointestinal hormone, which modulates physiological insulin secretion. Due to its insulinotropic activity, there has been a considerable increase of interest in utilising the hormone as a potential therapy for type 2 diabetes. One of the difficulties in attempting to harness the insulinotropic activity of GIP into an effective therapeutic agent is its short biological half-life in the circulation. However, recent years have witnessed the development of a substantial number of designer enzyme-resistant 'super GIP' molecules with potent insulinotropic and anti-diabetic properties. In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders. The present review aims to highlight the rapidly emerging potential therapeutic applications of GIP, and especially, enzyme-resistant GIP analogues. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码：253 / 263
页数：11
相关论文
共 107 条
  • [1] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
    Agerso, H
    Jensen, LB
    Elbrond, B
    Rolan, P
    Zdravkovic, M
    [J]. DIABETOLOGIA, 2002, 45 (02) : 195 - 202
  • [2] Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
    Ahrén, B
    Holst, JJ
    Mårtensson, H
    Balkan, B
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) : 239 - 245
  • [3] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
    Ahrén, B
    Simonsson, E
    Larsson, H
    Landin-Olsson, M
    Torgeirsson, H
    Jansson, PA
    Sandqvist, M
    Båvenholm, P
    Efendic, S
    Eriksson, JW
    Dickinson, S
    Holmes, D
    [J]. DIABETES CARE, 2002, 25 (05) : 869 - 875
  • [4] Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells
    Almind, K
    Ambye, L
    Urhammer, SA
    Hansen, T
    Echwald, SM
    Holst, JJ
    Gromada, J
    Thorens, B
    Pedersen, O
    [J]. DIABETOLOGIA, 1998, 41 (10) : 1194 - 1198
  • [5] [Anonymous], CAN J PHYSL PHARM
  • [6] Effects of gastric inhibitory polypeptide, somatostatin and epidermal growth factor on lipogenesis in ovine adipose explants
    Baba, ASH
    Harper, JMM
    Buttery, PJ
    [J]. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2000, 127 (02): : 173 - 182
  • [7] BAILEY CJ, 1982, INT J OBESITY, V6, P11
  • [8] IMMUNOREACTIVE GASTRIC-INHIBITORY POLYPEPTIDE AND K-CELL HYPERPLASIA IN OBESE HYPERGLYCEMIC (OB/OB) MICE FED HIGH-FAT AND HIGH-CARBOHYDRATE CAFETERIA DIETS
    BAILEY, CJ
    FLATT, PR
    KWASOWSKI, P
    POWELL, CJ
    MARKS, V
    [J]. ACTA ENDOCRINOLOGICA, 1986, 112 (02): : 224 - 229
  • [9] BAILEY CJ, 2003, TXB DIABETES, V1
  • [10] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
    Balkan, B
    Kwasnik, L
    Miserendino, R
    Holst, JJ
    Li, X
    [J]. DIABETOLOGIA, 1999, 42 (11) : 1324 - 1331
12345678910